GL1X · GenesisL1 explorer

Research workbench

X-ray crystallographic structure activity relationship (sar) of casimiroin and its analogs bound to human quinone reductase 2

Analyse X-ray crystallographic structure activity relationship (sar) of casimiroin and… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3NHR
Type
protein
Length
459 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Ribosyldihydronicotinamide dehydrogenase [quinone]
EC
1.10.99.2
UniProt
P16083
Ligands
RZW, FAD, ZN
Pockets
2 · best druggability 0.77

Structure

x-ray diffraction · 2 distinct chains · 41% helix, 16% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ARibosyldihydronicotinamide dehydrogenase [quinone] (EC 1.10.99.2)protein22941% helix, 16% strandP16083
BRibosyldihydronicotinamide dehydrogenase [quinone] (EC 1.10.99.2)protein23040% helix, 16% strandP16083

Ligands and binding sites

  • RZW · 5,6,8-trimethoxy-1,4-dimethylquinolin-2(1H)-one · ligand · 3 copies · chains A, B
  • FAD · Flavin-adenine dinucleotide · ligand · 2 copies · chains A, B
  • ZN · Zinc ion · metal · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
16010.770.8243FAD, RZW
26170.750.8145RZW, FAD

Interfaces

1 interface between chains.

  • A–B · 2022 Ų buried · 28 hydrogen bonds · protein-protein

Compared structures

  • 3NHR · X-ray Crystallographic Structure Activity Relationship (SAR) of Casimiroin and its… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.